Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis

Официальное название

Efficacy and Safety of Infliximab for Immune Checkpoint Inhibitor Induced Colitis: a Multinational, Randomised, Open Label, Phase III Trial - The iCaD Study

Обзор

The goal of this clinical trial is to assess whether the early introduction of biological treatment with a TNF-alpha inhibitor (infliximab) in addition to corticosteroids for severe ir-colitis/diarrhoea will reduce the time to grade ≤ 1 ir-colitis/diarrhoea compared to corticosteroids alone in patients scheduled for ICI treatment for solid tumors and untreated mCTCAE grade 2-4 diarrhoea or colitis. The main question it aims to answer is: • Can an early introduction of biological treatment with a TNF-alpha inhibitor (infliximab) in addition to corticosteroids reduce the time to grade ≤ 1 ir-colitis/diarrhoea compared to corticosteroids alone. Participants will be randomised 1:1: Arm A: All patients will receive same dose of methylprednisolone i.v. daily. Arm B: Patients allocated to Arm B will in addition receive infliximab i.v. day 1 or 2. Study patients are evaluated with blood samples, faecal samples and by sigmoidoscopy. Procedures are performed before randomisation and as part of follow up.

Вмешательства

• Препарат Infliximab
  Infliximab is available in vials of 100 mg with pharmaceutical form of concentrate for solution for infusion. Participating sites will ensure availability of infliximab as part of the hospital's standard supply for use in the study.
• Препарат Methylprednisolone
  Methylprednisolone is available in vials of 40 mg. Methylprednisolone is a drug used for standard treatment first line for ir-colitis or diarrhoea CTCAE grade ≥ 3. Participating sites will ensure availability of methylprednisolone for use in the study as part of the hospitals standard supply.
• Препарат Prednisolone
  Prednisolone is available in tablets of 25 or 5 mg. Oral corticosteroids are internationally recommended as initial treatment for ir-colitis and ir-diarrhoea CTCAE grade 2 \[24-27\]. Participating sites will ensure availability of prednisolone for use in the study as part of the hospitals' standard supply.

Первичные конечные точки

• Time (days) to persistent modified CTCAE grade ≤ 1 ir-colitis/diarrhoea. [Срок оценки: From the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: seven weeks)]

Вторичные конечные точки (9)

• Proportion of study subjects with grade ≤ 1 ir-colitis/diarrhoea at 72 hours. [Срок оценки: Time frame: 72 hours]
• Proportion of study subjects with persistent grade ≤ 1 ir-colitis/diarrhoea at three weeks. [Срок оценки: The event will be calculated from the first day of grade ≤ 1 ir-colitis/diarrhoea of that period (time frame: three weeks)]
• Proportion of study subjects with a corticosteroid-free clinical remission (grade ≤ 1 ir-colitis/diarrhoea) after seven weeks. [Срок оценки: Time frame: seven weeks]
• Proportion of study subjects requiring rescue immunosuppressive medication [Срок оценки: Time frame: seven days]
• Cumulative corticosteroid exposure [Срок оценки: Time frame: seven weeks]
• QoL by means of EORTC-QLQ-C30 [Срок оценки: Change in score from baseline to 3, 12, 24, and 52 weeks after randomisation]
• QoL by means of selected PRO-CTCAE items [Срок оценки: Change in score from baseline to 3, 12, 24, and 52 weeks after randomisation]
• Proportion of study subjects with treatment related adverse events as assessed by CTCAE v5.0 [Срок оценки: Time frame: 12 weeks]
• Proportion of study subjects with colectomy or colitis-specific mortality [Срок оценки: Time frame: seven weeks]

Критерии участия

Критерии включения

• Untreated mCTCAE grade 2-4 diarrhoea or colitis, or persistent mCTCAE grade 2 diarrhoea after administration of loperamide or equivalent for mCTCAE grade ≤ 2 diarrhoea
• No signs of colonic perforation or infection
• Age ≥ 18
• Understands the nature and purpose of the study and the study procedures and has signed informed consent
• Is able to read, understand, and complete questionnaires and daily components of the patient Diary for the study period
• Histologically confirmed malignant solid tumours
• Treatment with immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1 or anti-PD-L1) within the past 12 weeks. Immune checkpoint inhibitors can be administered as single agents or as combination therapy with anti-CTLA-4 and anti-PD-1
• No probability of a concomitant treatment (e.g. laxatives) other than the immune checkpoint inhibitor being the causal drug for the colitis or diarrhoea
• Prior treatment with immune checkpoint inhibitors is allowed
• Usage of prednisolone ≤ 10 mg daily for non irAE is allowed
• Diagnostic work up including screening for viral hepatic infection and QuantiFERON-TB for mycobacterium tuberculosis must be requisitioned but will not need to be reported prior to study enrolment
• Women of child bearing potential must have a negative serum (preferred) or urine pregnancy test within 72 hours prior to registration.

• Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e. females who have had evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrheic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antiestrogens, low body weight, ovarian suppression or other reasons.
• Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and after the study treatment:

• for at least 6 months after the last study treatment, or depending on the duration antineoplastic treatment
• Note: A highly effective method of birth control is defined as a method which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Such methods include:

• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
• Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
• Vasectomized partner
• Sexual abstinence

Критерии исключения

• Prior history of inflammatory bowel disease, colitis, or diarrhoea requiring treatment with any corticosteroid, or any other immunosuppressant medication
• Prior history of recurrent bowel disease including symptomatic diverticulosis
• Current positive testing for Clostridium difficile or other colonic infection
• Current bacterial infection requiring antibiotic treatment, or systemic fungal infection
• Ongoing antibiotic treatment for any reason
• Treatment with systemic corticosteroids within the last four weeks prior to study enrolment (daily usage of prednisolone ≤ 10 mg for non irAE conditions is accepted)
• Concurrent immune-related adverse events requiring immunosuppressant medication of any kind
• Known hypersensitivity or contraindications to systemic corticosteroids or infliximab
• Prior history of viral hepatitis with a positive viral load, known untreated mycobacterium tuberculosis, or known active herpes zoster infection

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Дания · 2 центра

• Department of Oncology, Aalborg University Hospital — Aalborg
• Department of Oncology Odense University Hospital — Odense

Великобритания · 1 центр

• The Royal Marsden Hospital — London

Идентификаторы

NCT: NCT05947669 · The ICaD Study

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗